ADXN · Addex Therapeutics Ltd.
$5.95
At close · Aug 10
Market Cap
$7.34M
Shares
1.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.95
Open$5.95
Day$5.95–5.95
52W close$5.20–10.95
Avg vol 30d4K
Short int4K · 0.3% float · 3.8d
Short vol8%
Last earningsSep 30, 2025
DataOct 2023–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Oct 23, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−5%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
13%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−28%
trailing
YTD return
−23%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.33% of float · ▲ +351.4% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score
47
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−5%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
13%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.33% of float · ▲ +351.4% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $5
Now $6 · 13%
Range high $11
vs 200-day avg -21%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADXN
this stock
Addex Therapeutics Ltd.
|
$7.34M | -22.9% | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
2
- % held
- 0.0%
- Net QoQ
- -407 sh
- Top holder
- UBS Group AG
Held
Float
Short & Settlement
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Oct 23, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADXN | +1.1% | +0.2% | -27.5% | +14.4% | -22.9% |
| SPY | +2.0% | +3.2% | +13.2% | +3.5% | +13.4% |
| vs SPY | -0.9% | -3.0% | -40.7% | +10.9% | -36.3% |